On August 24, 2020, Heat Biologics, Inc. (the "Company reported the Sales Agreement dated April 3, 2019, as amended on April 23, 2020, between the Company and B. Riley Securities, Inc. (formerly known as B. Riley FBR, Inc.) to include Cantor Fitzgerald & Co. as an additional sales agent for the Company’s "at the market offering" program (the "Sales Agreement") (Filing, 8-K, Heat Biologics, AUG 24, 2020, View Source [SID1234563964]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Sales Agreement is filed as Exhibit 1.1 to this report and the foregoing description of the Sales Agreement is qualified in its entirety by reference to such exhibit.

As of August 20, 2020, the Company has sold 22,831,760 shares of its common stock having an aggregate offering price of $50,614,448 under a sales agreement with B. Riley Securities, Inc. pursuant to a prospectus supplement dated July 27, 2020, relating to the offer and sale of shares of its common stock, having an aggregate offering price of up to $100,000,000.

This Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

The information contained in this Form 8-K (including the exhibits hereto) is hereby incorporated by reference into the Company’s Registration Statement on Form S-3 (Registration No. 333-237808).